Can Ruti Campus remains a globally significant scientific centre due to its medical and research staff

Once again, the names of around thirty renowned professionals - from the Hospital and the Germans Trias i Pujol Research Institute (IGTP), the Fight Infections Foundation, IrsiCaixa, the Josep Carreras Leukaemia Research Institute (IJC), and the Institut Català d'Oncologia (ICO) - appear on a global list of scientists who have achieved the highest impact through their publications and citations.

Can Ruti welcomes students from Badalona for the Science Week

Nearly 200 baccalaureate and vocational training students from the Badalona institutes visited the centres at the Can Ruti Campus. The event "Open House, get to know the Can Ruti Campus up close", organised by the Badalona Education Service and IGTP, in coordination with other institutions on the Campus, has become a flagship initiative of the Science Week.

Translational Program in Cancer Research II Workshop: A hub for research and collaboration

The second CARE Workshop, held on 9-10 October, brought together more than 70 researchers from across the cancer research community at the Can Ruti Biomedical Campus for two days of scientific exchange. The event served as a platform for sharing the current cancer research being developed on the Campus and fostering stronger connections among researchers.

Researcher Sofía España receives a €140,000 grant from the Spanish Association Against Cancer

Dr Sofía España, a researcher from the Cancer Mechanisms and Pathways Group at IGTP and the Badalona Applied Research Group in Oncology (B·ARGO) IGTP-Institut Català d'Oncologia (ICO), has been awarded one of the prestigious Clínico Junior Grants by the Spanish Association Against Cancer. This grant will enable her to balance her clinical duties with research, focusing on the development of a minimally invasive diagnostic tool to classify different types of colorectal cancer, advancing towards precision medicine.

New therapeutic strategy for metastatic prostate cancer patients resistant to standard treatment

Researchers from B·ARGO and the Urological Tumour Unit at IGTP and ICO have led a study proposing a new therapeutic strategy based on a combination of kinase inhibitors for metastatic prostate cancer patients who have progressed on standard treatment. The study has been published in the journal Frontiers in Pharmacology.

Agarose-based method shows potential in understanding extracellular vesicles' role in cancer metastasis

A collaborative study led by researchers from IGTP has revealed the promising possibilities of using an agarose spot migration assay to examine the ability of extracellular vesicles to attract other cells in a controlled environment. The study has been recently published in the journal BMC Biology.

InMaM project: innovative immunotherapies to treat breast cancer

The collaborative project InMaM, part of the Complementary Plan for Biotechnology Applied to Health, involving both Catalonia and the Basque Country, aims to discover new immunotherapy-based treatments for metastatic breast cancer.

IGTP researchers engage in World Cancer Research Day with talks and workshops

• In collaboration with the Badalona City Council, a series of events and talks organised to mark the 40th anniversary of the Germans Trias Hospital will deal with topics related to science and health.
• The event on Sunday at the Badalona Museum is organised by Amics de Can Ruti and will feature researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Catalan Institute of Oncology (ICO).

New lung cancer treatment boosts survival and could benefit more than 6,000 patients a year

A new lung cancer treatment has allowed 36.8% of patients to achieve complete tumour disappearance, compared to the 6.9% rate of the standard post-surgery treatment. In addition, 85% of patients survive two years after receiving chemo-immunotherapy before surgery compared to 63% who receive chemotherapy alone before surgery. The study involved oncologist from ICO Badalona and IGTP researcher, Teresa Morán.

A study of patients with ovarian cancer highlights the need to identify the mechanisms of resistance to PARP inhibitors to find effective therapies for this tumour

Retreatment with platinum-based chemotherapy as a therapy for relapsed ovarian cancer after progression to PARP inhibitors shows different results for patients with BRCA-mutated and BRCA wild-type tumours.